Pradaxa Reversal Agent Approved
In 2010, the FDA approved the prescription blood-thinning drug Pradaxa (dabigatran) to prevent stroke and systemic blood clots in patients with atrial fibrillation, as well as for the treatment and prevention of deep venous thrombosis and pulmonary embolism. On October 16, 2015, the FDA granted acc[...]